Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears

What happened

Amgen reported positive Phase 3 results for dazodalibep in Sjögren’s disease, a chronic autoimmune condition affecting moisture-producing glands. Both treatment groups met the trial’s primary endpoint at Week 48, with systemic disease activity scores falling more than with placebo. The full data were presented at ACR Convergence 2026.

Confirmed

Global impact / market context

The results could support Amgen’s effort to develop a treatment for a disease the article says has no U.S.-approved therapies. If later evidence and regulatory review support approval, a new treatment could create sales for Amgen and give patients another option; approval is not established here.

Analyst inference

Phase 3 is a late-stage clinical trial, and meeting its main goal is a positive development, but these results alone do not establish approval or commercial success. The article provides no sales forecast, regulatory decision, or financial impact, so the investment effect remains uncertain.

Analyst inference

What to watch

1. Further details on symptom outcomes and safety could clarify whether the reported disease-activity improvement offers meaningful benefits to patients beyond the trial’s primary measure. Analyst inference
2. Any future U.S. regulatory submission or decision would determine whether dazodalibep can be sold as a treatment for Sjögren’s disease; the article reports no such action. Analyst inference
3. Amgen’s later disclosures on development plans, trial evidence, and potential commercial opportunity would help investors judge whether these results could translate into future revenue. Analyst inference

Evidence

• Original source link unavailable